From the Guidelines
It is not recommended to take Alvesco (ciclesonide) and Advair (fluticasone/salmeterol) at the same time without medical supervision, as this may increase the risk of side effects such as oral thrush, hoarseness, and adrenal suppression. Both medications contain inhaled corticosteroids, which could lead to an increased risk of adverse effects when used together 1. Advair already contains both a corticosteroid (fluticasone) and a long-acting beta-agonist (salmeterol), while Alvesco is a standalone corticosteroid inhaler.
If you're considering using both, it's essential to consult with your healthcare provider first, as they may have specific reasons for prescribing both medications, such as difficult-to-control asthma or COPD 2. They would provide instructions on proper timing and dosing, and monitor you more closely for potential adverse effects from the combined corticosteroid exposure. The combination of inhaled corticosteroids and long-acting beta-agonists has been shown to improve lung function, health-related quality of life, and reduce the frequency of exacerbations in patients with COPD 1. However, the use of multiple inhaled corticosteroids, such as Alvesco and Advair, is not recommended without medical supervision due to the increased risk of side effects.
Some key points to consider when using these medications include:
- Separating the administration times by at least 5-10 minutes to minimize side effects
- Rinsing your mouth after using each inhaler to reduce the risk of oral thrush and hoarseness
- Monitoring for potential adverse effects, such as adrenal suppression, and reporting any concerns to your healthcare provider
- Following the instructions provided by your healthcare provider for proper use and dosing of these medications.
From the Research
Medication Interaction
- Alvesco (ciclesonide) and Advair (fluticasone propionate/salmeterol) are both used to treat asthma, but they have different mechanisms of action and properties.
- According to the study 3, intranasal ciclesonide coadministration with inhaled fluticasone propionate-salmeterol does not suppress cortisol in allergic rhinitis patients, suggesting that the combination may be safe in terms of cortisol suppression.
- The study 4 characterized the pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma, and found that ciclesonide showed the least serum cortisol suppression of the tested dosing regimens.
Efficacy and Safety
- The study 5 compared the effect of low-dose ciclesonide and fixed-dose fluticasone propionate and salmeterol combination on long-term asthma control, and found that both treatments were effective in controlling asthma symptoms.
- The study 6 reviewed the safety and efficacy of ciclesonide as an inhaled corticosteroid for the treatment of asthma, and found that it is a safe and effective treatment option with a low oral and systemic bioavailability.
- The study 7 discussed the use of combination treatment with fluticasone propionate and salmeterol (Advair) for the treatment of asthma, and found that it provides greater asthma control than increasing the dose of inhaled corticosteroid alone.
Combination Therapy
- The studies suggest that combination therapy with ciclesonide and fluticasone propionate/salmeterol may be a viable treatment option for asthma, with potential benefits in terms of efficacy and safety.
- However, it is essential to consult with a healthcare professional to determine the best treatment plan for individual patients, as the safety and efficacy of combination therapy may vary depending on individual factors.